

**Supplementary Table 1 – an overview of all extrapolation data used and reasoning behind their use.**

	<b>IQVIA</b>	<b>PHARMO</b>	<b>Hospitalization</b>	<b>Claims</b>	<b>Explanation</b>
Database coverage estimates	57%	28,3	N/a	N/a	Coverage of database as reported by each company.
Percentage untreated patients	48%	48%	N/a	N/a	Percentage of NTM-PD patients not treated with antibiotics determined as the average of previous differing findings in Germany and the UK <sup>12-13</sup> .
Percentage NTM-PD treatment not captured	20%	20%	N/a	N/a	Patients receiving treatment for rapidly growing NTM are not captured in included regimens. Proportion of NTM-PD patients with rapidly growing NTM based on previous estimates in 5 European countries <sup>14</sup> .
Percentage of patients hospitalized	N/a	N/a	14.7%	N/a	The percentage of patients hospitalized is extrapolated from findings in Germany. Where two studies showed a hospitalization rate of 0.91 / 100,000 (2005-2011) and disease prevalence of 6.2 / 100.000 (2016) <sup>6,16</sup> .
Sensitivity of ICD-10 codes	N/a	N/a	N/a	50%	Sensitivity of ICD-10 coding was based on previous findings specific to ICD-10 code A31.0 (NTM-PD) in the US <sup>15</sup> .